INTRODUCTION
♦ With the increasing prevalence of type 2 diabetes mellitus (T2DM) in Taiwan, cost-effective treatments are needed 1, 2 ♦ Dulaglutide, a once-weekly glucagon-like peptide-1 receptor agonist, has been developed as a treatment for T2DM
♦ The AWARD (Assessment of Weekly AdministRation of dulaglutide in Diabetes) clinical trial program assessed the efficacy of dulaglutide against comparators including exenatide, insulin glargine, metformin, sitagliptin, and liraglutide
• In the AWARD-6 trial, once-weekly dulaglutide 1.5 mg showed non-inferiority to once-daily liraglutide 1.8 mg 3 ♦ Presented here are cost-effectiveness analyses of dulaglutide and liraglutide (the relevant comparator in Taiwan), which formed the basis of a reimbursement submission in Taiwan 
Base Case Assumptions

Treatment and Management Costs
♦ The analyses were conducted from the perspective of the Taiwanese National Health Insurance Administration (NHIA) capturing the following direct medical costs (Table 4) :
• Treatment costs, including drug costs, costs associated with self-monitoring of blood glucose, needle costs (where applicable), and complication costs
• Management costs, including costs associated with cardiovascular and renal complications, hypoglycemia, eye disease, and ulcer/amputation/neuropathy 
RESULTS
Base Case Results
♦ Under base case assumptions:
• Dulaglutide 1.5 mg was dominant (less costly and more effective) compared with liraglutide 1.8 mg (Table 5) • Dulaglutide 1.5 mg and 0.75 mg were also cost effective compared with liraglutide 1.2 mg (Table 5) Handling of Uncertainty ♦ One-way sensitivity analyses (OWSA) and probabilistic sensitivity analyses (PSA) were conducted to explore the model's sensitivity to specific parameters and overall uncertainty
Treatment Effects
♦ Mean treatment effects for glycosylated hemoglobin (HbA1c), body mass index, and nausea were taken from outputs of the NMA and applied in the first year of treatment (Table 2) ♦ Inputs not provided from the NMA (blood pressure, lipids, hypoglycemic events) were taken from the AWARD-6 and AWARD-2 dulaglutide treatment arms and applied to both arms 
